References
- American Psychiatric Association., American Psychiatric Association. DSM-5 task force. Diagnostic and statistical manual of mental disorders : dSM-5. 5th ed. WA D.C: American Psychiatric Association; 2013.
- Cortese S, Song M, Farhat LC, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the global burden of disease study. Mol Psychiatry. 2023 Sep 8;28(11):4823–4830. doi: 10.1038/s41380-023-02228-3
- Song P, Zha M, Yang Q, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021 Feb 11;11:04009. doi: 10.7189/jogh.11.04009
- Meinzer MC, LeMoine KA, Howard AL, et al. Childhood ADHD and involvement in early pregnancy: mechanisms of risk. J Atten Disord. 2020 Dec;24(14):1955–1965.
- Raggi VL, Chronis AM. Interventions to address the academic impairment of children and adolescents with ADHD. Clin Child Fam Psychol Rev. 2006 Jun;9(2):85–111. doi: 10.1007/s10567-006-0006-0
- Harpin V, Mazzone L, Raynaud JP, et al. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016 Apr;20(4):295–305.
- Fuermaier ABM, Tucha L, Butzbach M, et al. ADHD at the workplace: ADHD symptoms, diagnostic status, and work-related functioning. J Neural Transm (Vienna). 2021 Jul;128(7):1021–1031.
- Burns AB, Garner AA, Avion A, et al. ADHD and dangerous driving in emerging adults: the moderating role of family climate for road safety. Accid Anal Prev. 2022 Dec;178:106819. doi: 10.1016/j.aap.2022.106819
- Michielsen M, Comijs HC, Aartsen MJ, et al. The relationships between ADHD and social functioning and participation in older adults in a population-based study. J Atten Disord. 2015 May;19(5):368–379.
- Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: a historical perspective. Pediatrics. 2019 Oct;144(4). doi: 10.1542/peds.2019-1682
- Lovett BJ, Nelson JM. Systematic review: educational accommodations for children and adolescents with attention-Deficit/Hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2021 Apr;60(4):448–457. doi: 10.1016/j.jaac.2020.07.891
- Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Health. 2018 Nov;21(4):173–176. doi: 10.1136/ebmental-2018-300050
- Steingard R, Taskiran S, Connor DF, et al. New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019 Jun;29(5):324–339.
- Highlights of prescribing information Strattera® (atomoxetine) capsules for oral use. [cited 2023 Sep 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411
- Highlights of Prescribing Information. INTUNIV® (guanfacine) extended-release tablets, for oral use. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
- Highlights of Prescribing Information. KAPVAY® (clonidine hydrochloride) extended-release tablets, for oral use. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf
- Highlights of Prescribing Information. QelbreeTM (viloxazine extended-release capsules). [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727–738.
- Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171–179.
- Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008 Jan;121(1):e73–e84.
- Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020 Jan;24(2):348–358.
- Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018 Oct;5(10):824–835.
- Highlights of prescribing information focalin XR (dexmethylphenidate hydrochloride) extented-release capsules, for oral use, CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021802s038s041lbl.pdf
- Highlights of Prescribing Information. Mydayis (mixed salts of a single-entity amphetamine product) extended-release capsules, for oral use, CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022063s005lbl.pdf
- Highlights of Prescribing Information. Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, for oral use, CII. [cited 2024 Feb 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf
- Highlights of Prescribing Information. Concerta (methylphenidate HCl) extended-release tablets, CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s049lbl.pdf
- Highlights of Prescribing Information. Metadate CD® (methylphenidate HCl, USP) Extended-Release Capsules. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021259s034lbl.pdf
- Wigal SB, Childress AC, Belden HW, et al. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013 Feb;23(1):3–10.
- Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr. 2006 Oct;45(8):725–733. doi: 10.1177/0009922806292786
- Highlights of Prescribing Information. Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablets), CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204326s011lbl.pdf
- Highlights of Prescribing Information. Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205489s012lbl.pdf
- Highlights of Prescribing Information. Quillichew ER™ (methylphenidate hydrochloride) extended-release chewable tablets, for oral use, CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207960orig1s016lbl.pdf
- Highlights of prescribing information quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII. [cited 2024 Feb 19]. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202100Orig1s023lbl.pdf
- Highlights of prescribing information Daytrana® (methylphenidate transdermal system), CII. [cited 2024 Feb 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021514s036lbl.pdf.
- Wolraich ML, Hagan JF Jr., Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4). doi: 10.1542/peds.2019-2528
- Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581–588.
- Chung W, Jiang SF, Paksarian D, et al. Trends in the prevalence and incidence of attention-Deficit/Hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Netw Open. 2019 Nov 1;2(11):e1914344. doi: 10.1001/jamanetworkopen.2019.14344
- Danielson ML, Bohm MK, Newsome K, et al. Trends in stimulant prescription fills among commercially insured children and adults - United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2023 Mar 31;72(13):327–332. doi: 10.15585/mmwr.mm7213a1
- Top 25 Psychiatric Medications for. 2022 Nov [cited 2024 Feb 19]. Available from: https://psychcentral.com/blog/top-25-psychiatric-medications-for-2020#top-25-list
- Childress AC. Stimulants. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):373–392. doi: 10.1016/j.chc.2022.03.001
- Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-Deficit/Hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022 Sep 1;42(5):429–439. doi: 10.1097/JCP.0000000000001575
- Surman CBH, Walsh DM, Horick N. et al. Solriamfetol for attention-Deficit/Hyperactivity disorder in adults: a double-blind placebo-controlled Pilot study. J Clin Psychiatry. 2023 Oct 9;84(6). doi: 10.4088/JCP.23m14934
- Surman C, Vaudreuil C, Boland H, et al. L-threonic acid magnesium salt supplementation in ADHD: an open-label pilot study. J Diet Suppl. 2020 Mar;12:1–13.
- Childress AC, Brams M, Koehn K, et al. A phase 3, dose-optimized, double-blind, randomized, placebo controlled, single-center, parallel efficacy and safety laboratory classroom study in adults with attention deficit/hyperactivity disorder (ADHD) using CTX-1301 (dexmethylphenidate) presented at psych congress. Nashville TN; 2023 Sep 7–10.
- U.S. Food and Drug Administration NDA 215401 NDA approval. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215401Orig1s000ltr.pdf
- NDA 215401 multi-disciplinary review and evaluation xelstrym (dextroamphetamine transdermal system; d-ATS). [cited 2023 Oct 29]. Available from: https://www.fda.gov/media/158282/download
- Highlights of prescribing information Xelstrym® (dextroamphetamine) transdermal system, CII. [cited 20 Oct 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215401s008lbl.pdf
- Castelli M, Suzuki K, Starling B, et al. Extrapolation of efficacy of a dextroamphetamine transdermal system from pediatric to adult populations using pharmacokinetic modeling. Presented at the American Society of Clinical Psychopharmacology Annual Meeting. 2022 May 31 to June 3, Scottsdale, AZ.
- Cutler AJ, Suzuki K, Starling B, et al. Efficacy and safety of dextroamphetamine transdermal system for the treatment of attention-Deficit/Hyperactivity disorder in children and adolescents: results from a pivotal phase 2 study. J Child Adolesc Psychopharmacol. 2022 Mar;32(2):89–97. doi: 10.1089/cap.2021.0107
- Cutler AJ, Suzuki K, Starling B, et al. D-amphetamine transdermal system in treatment of children and adolescents with attention-Deficit/Hyperactivity disorder: secondary endpoint results and post hoc effect size analyses from a pivotal trial. J Child Adolesc Psychopharmacol. 2023 Jun;33(5):176–182. doi: 10.1089/cap.2023.0005
- Cutler AJ, Childress AC, Pardo A, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-Deficit/Hyperactivity disorder. J Clin Psychiatry. 2022 Jul 20;83(5). doi: 10.4088/JCP.22m14438
- Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008 Jun;47(6):700–708.
- Surman C, Vaudreuil C, Boland H, et al. L-Threonic acid magnesium salt supplementation in ADHD: an open-label pilot study. J Diet Suppl. 2021;18(2):119–131. doi: 10.1080/19390211.2020.1731044